Understanding heart muscle changes in hypertrophic cardiomyopathy to predict serious heart events
Official title: Proteomics profiling in hypertrophic cardiomyopathy and cardiac event prediction
Funded at Columbia University Health Sciences · NIH-11063799 · Data updated 2026-11-12
This study is looking at hypertrophic cardiomyopathy (HCM), a heart condition that can cause serious problems, to find out how it affects people and to help doctors better predict who might be at risk for complications, so they can provide better care over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $614,874 |
| NIH project number | 5R01HL157216-05 |
| Project ID | NIH-11063799 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those who may be at risk for major adverse cardiovascular events.
✕Less likely to help
Patients without a diagnosis of hypertrophic cardiomyopathy or those with other unrelated cardiac conditions may not benefit from this research.
What this research studies
This research investigates hypertrophic cardiomyopathy (HCM), a common genetic heart condition that can lead to serious cardiovascular events like arrhythmias and heart failure. By analyzing blood and heart tissue samples from patients in a large biorepository, the study aims to identify specific molecular changes associated with HCM and its complications. The goal is to improve the ability to predict which patients are at higher risk for adverse events, thereby guiding more effective preventive treatments. Patients will be followed closely over several years to gather comprehensive health data.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of serious heart events in patients with hypertrophic cardiomyopathy, allowing for timely and targeted interventions.
How similar studies have gone: Previous research has shown promise in using proteomic profiling to understand heart diseases, suggesting that this approach could yield valuable insights for hypertrophic cardiomyopathy as well.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Shimada, Yuichi — Columbia University Health Sciences
- Study coordinator: Shimada, Yuichi
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.